Waylivra market seen growing through 2030 as rare disease demand rises
The Business Research Company says the Waylivra market is set for meaningful growth through 2030, driven by better genetic testing, more awareness of rare lipid disorders and wider use of targeted therapies. Europe is expected to hold the largest share in 2025 as healthcare spending and genomic diagnostics support adoption.
Why it matters: - The Waylivra market is expanding as rare lipid disorders receive more attention from clinicians, researchers and payers. - Growth in genetic medicine could increase demand for targeted therapies used to lower triglycerides and reduce pancreatitis risk. - Wider access to diagnostic tools and rare-disease care may improve treatment rates across major markets.
What happened: - The Business Research Company published a new market analysis on Waylivra, also known as volanesorsen. - The report says the market is gaining momentum and is expected to see significant growth through 2030. - A free sample of the report is available here. - The full report is available here.
The details: - Waylivra is a specialized medicine for a rare genetic disorder marked by extremely high triglyceride levels. - The drug blocks production of ApoC-III, a protein tied to triglyceride metabolism. - Lower ApoC-III activity reduces triglyceride concentrations and helps lower pancreatitis risk. - The company links past market expansion to better diagnostics for rare lipid conditions, progress in antisense oligonucleotide therapies, growth of specialty lipid clinics, awareness of pancreatitis risks and orphan drug incentives. - The report says future growth will be supported by more investment in genetic medicine research, broader use of targeted metabolic treatments, personalized lipid management strategies, better access to rare-disease therapies and greater use of genomic diagnostics. - Key trends include more RNA-targeted treatments, stronger focus on rare lipid disorders, expanded genetic screening and better monitoring of lipid metabolism outcomes. - The report says increased prevalence of rare genetic disorders is a major driver of demand. - In May 2024, the UK National Health Service said about 17,000 people in England live with sickle cell disease and about 250 new diagnoses are made each year. - The report also points to rising healthcare spending as a catalyst for adoption. - UK healthcare spending reached £317 billion in 2024, according to provisional April 2025 data from the Office for National Statistics. - That represented 6.5% nominal growth and 2.4% real growth from 2023. - Long-term care spending rose 3.1% in real terms in 2023, driven largely by government funding. - Europe is expected to hold the largest share of the Waylivra market in 2025. - The regional outlook in the report also covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.
Between the lines: - The market case depends less on a single breakthrough and more on a stack of enabling trends: screening, diagnosis, specialty care and reimbursement-friendly rare-disease frameworks. - Europe’s expected lead suggests established healthcare systems and rare-disease infrastructure may be giving the region an early advantage. - The inclusion of healthcare spending data signals that the market’s growth story is being tied to broader system capacity, not just drug-level demand.
What's next: - The market will likely track progress in genetic testing, rare-disease identification and broader use of RNA-targeted therapies. - Europe’s share will be a key benchmark for how quickly other regions can scale access to Waylivra and similar treatments. - The report’s updated forecasting tools suggest more attention will shift toward identifying market hotspots and near-term adoption opportunities.
The bottom line: - Waylivra’s growth outlook is being fueled by rare-disease awareness, better diagnostics and rising healthcare investment, with Europe positioned to lead near term.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Europe Daily Report
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.